|
| Dyspnea | 117 (28.8) |
| Chest pain | 81 (20) | |
| Performance status (PS) | 0 - 1 | 264 (65.2) |
| 2 | 89 (22) | |
| 3 - 4 | 52 (12.9) | |
| Histological type | Adenocarcinoma | 241 (59.5) |
| Squamous cell carcinoma | 91 (22.5) | |
| Undifferentiated carcinoma | 54 (13.3) | |
| Neuroendocrine carcinoma | 11 (2.7) | |
| Sarcomatoid carcinoma | 5 (1.3) | |
| Carcinoid tumor | 3 (0.7) | |
| Tumor size | T1 | 4 (1) |
| T2 | 28 (7) | |
| T3 | 122 (30) | |
| T4 | 251 (62) | |
| Lymph node involvement | N1 | 146 (36) |
| N2 | 117 (29) | |
| N3 | 142 (35) | |
| Metastatic sites | Lung | 204 (50.4) |
| Bone | 132 (32.6) | |
| Pleura | 89 (22) | |
| Brain | 86 (21.2) | |
| Liver | 71 (17.5) | |
| Number of metastatic sites | 1 | 247 (61) |
| >1 | 158 (39) | |
| Biological disturbances | Anemia | 238 (58.8) |
| Hyperleukocytosis | 186 (45.9) | |
| Thrombocytosis | 56 (13.8) | |
| Hypoalbuminemia | 201 (49.6) | |
| High LDH level | 139 (34.3) | |
| High LAP rate | 117 (29) | |
| High level of CRP (>10 ng/l) | 322 (79.5) | |
| Hypercalcemia | 16 (4) | |
| First line treatment | Conventional chemotherapy | 353 (87.1) |
| TKI anti-EGFR | 10 (2.5) | |
| Supportive care | 42 (10.4) | |
| Conventional chemotherapy | Platinum based doublet | 247 (70) |
| Platinum based doublet + BEVACIZUMAB | 46 (13) | |
| NAVELBINE (monotherapy) | 60 (17) |